OUTCOMES OF INTRAVESICAL EPIRUBICIN IN NON–MUSCLE-INVASIVE BLADDER CANCER AT NGHE AN ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objectives: To evaluate the clinical and paraclinical characteristics, as well as the outcomes of intravesical Epirubicin therapy for non-muscle invasive bladder cancer (NMIBC) at Nghe An Oncology Hospital from January 2020 to June 2023.
Methods: A retrospective descriptive study was conducted on 38 patients with non–muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor (TURBT) followed by adjuvant intravesical Epirubicin instillation between January 2020 and June 2023.
Results: The mean age was 66.42 ± 8.48 years; males accounted for 84.2%. Stage Ta and T1 represented 68.4% and 31.6%, respectively; 63.2% had high-grade histology. The mean follow-up duration was 32.11 ± 16.48 months. The recurrence rate was 21.1%. Disease-free survival rates at 12, 24, and 36 months were 86.3%, 83.2%, and 79.5%, respectively. Adverse events were mostly mild and well tolerated. Multivariate regression analysis showed that tumor size ≥ 3 cm, T1 stage, and high-grade histology were independent prognostic factors associated with recurrence (p < 0.05).
Conclusion: Epirubicin effectively reduces recurrence rates with a favorable safety profile and minimal side effects. Tumor size, stage, and grade constitute independent prognostic factors for disease recurrence (p < 0.05)
Keywords
Non–muscle-invasive bladder cancer, intravesical epirubicin, prognostic factors.
Article Details
References
2. Chen, F. et al. Efficacy and safety of short-term intravesical gemcitabine vs. long-term intravesical epirubicin in the treatment of moderate to high-risk non-muscle-invasive bladder cancer: a pilot study. Holist. Integr. Oncol. 3, 8 (2024).
3. Đỗ Anh Tú & Trịnh Lê Huy. Đặc điểm lâm sàng, cận lâm sàng của bệnh nhân Ung thư bàng quang nông được điều trị bổ trợ bàng epirubicin nội bàng quang tại Bệnh viện K. Tạp chí y học Việt Nam (2023).
4. Lê Đình Khánh, Hoàng Văn Tùng & Đoàn Quốc Huy. Đánh giá kết quả sớm điều trị u bàng quang nông bằng cắt đốt nội soi kết hợp Doxorubicin một liều duy nhất sau mổ.Tạp chí Y học TP Hồ Chí Minh. 283–288 (2012).
5. Zainfeld, D. & Daneshmand, S. Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies. Curr. Urol. Rep. 18, 34 (2017).
6. Daryanto, B., Purnomo, A. F., Seputra, K. P., & Budaya, T. N. (2022). Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. Medical Archives, 76(3), 198–201. https://doi.org/10.5455/medarh.2022.76.198-201
7. Ryoji, O. et al. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women’s Medical College Bladder Cancer Collaborating Group. Cancer Chemother. Pharmacol. 35 Suppl, S60-64 (2015).
8. Kuroda, M. et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. Eur. Urol. 45, 600–605 (2004).
9. Nguyễn Quỳnh Hương. Kết Quả Điều Trị Bổ Trợ Ung Thư Bàng Quang Nông Bằng Epirubicin Nội Bàng Quang Tại Bệnh Viện K. Tạp chí Y Học Việt Nam. tr22-23 ( 2023).